MedTrace Logo

[18F]-F13640 as a New Brain Radiopharmaceutical

NCT03347331 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-09-12

No results posted yet for this study

Summary

This clinical assay is designed to validate that \[18F\]F13640 as a radiotracer of 5-HT1A functional receptors. A first group of healthy subjects underwent a PET scan with arterial blood sampling to determine the kinetic model of the tracer. A second group of healthy subjects underwent a classical test-retest study (i.e two distant PET scans) to determine the reproducibility of measures.

Conditions

  • Neurological Pathology
  • Healthy Subjects

Interventions

DRUG

[18F]F13640

Radiotracer injection and PET scan acquisition of 90 min: \*150 Mbq + 1 MBq/Kg of \[18F\]F13640 at t=0 min Arterial Blood Sampling during the 90min acquisition

DRUG

[18F]F13640

2 Radiotracer injections and PET scan acquisition of 90 min distant from 1 to 3 weeks: For each exam: 150 MBq + 1 MBq/kg of \[18F\]F13640 at t=0 min

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • Scheiber Christian · Hospices Civils de Lyon

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-23
Primary Completion
2021-04-23
Completion
2021-12-02

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03347331 on ClinicalTrials.gov